aVLFA0822p Pharmacology II - lecture

Faculty of Medicine
spring 2021
Extent and Intensity
2/0/0. 4 credit(s). Type of Completion: zk (examination).
Teacher(s)
doc. MUDr. Regina Demlová, Ph.D. (lecturer)
doc. PharmDr. Jan Juřica, Ph.D. (lecturer)
Mgr. Petra Amchová, Ph.D. (lecturer)
doc. RNDr. Ladislava Bartošová, Ph.D. (lecturer)
Mgr. Jana Kubátová, Ph.D. (lecturer)
doc. Mgr. MVDr. Leoš Landa, Ph.D. (lecturer)
Mgr. Kristýna Nosková, Ph.D. (lecturer)
MUDr. Jana Nováková, Ph.D. (lecturer)
MUDr. Jana Pistovčáková, Ph.D. (lecturer)
doc. PharmDr. Jana Rudá, Ph.D. (lecturer)
PharmDr. Jitka Rychlíčková, Ph.D. (lecturer)
Mgr. Barbora Říhová, Ph.D. (lecturer)
doc. PharmDr. Ondřej Zendulka, Ph.D. (lecturer)
Róbert Balog (assistant)
Renata Bláblová (assistant)
Agnesa Gabuľová (assistant)
Květoslava Sedlářová (assistant)
Filip Šiška (assistant)
PharmDr. Eva Vohlídalová (assistant)
PharmDr. Katarína Kostolanská (alternate examiner)
Guaranteed by
doc. MUDr. Regina Demlová, Ph.D.
Department of Pharmacology - Theoretical Departments - Faculty of Medicine
Contact Person: doc. PharmDr. Ondřej Zendulka, Ph.D.
Supplier department: Department of Pharmacology - Theoretical Departments - Faculty of Medicine
Prerequisites (in Czech)
aVLFA0721p Pharmacology I - lecture && aVLPF0622p Pathophysiology II - lecture
Course Enrolment Limitations
The course is also offered to the students of the fields other than those the course is directly associated with.
fields of study / plans the course is directly associated with
Course objectives
The aim of the course is to acquiant the students with drugs from selected pharmacotherapeutic groups.
Learning outcomes
At the end of the course student should be able choose and prescribe suitable drug for the patient with known indicication. The selection will be made with respect to all factors influencing drug safety and efficacy.
Syllabus
  • aVLFA0822p - Pharmacology II lecture

    Spring semester 2020

    17:00-18:40 A11/114

  • 18. 2. 2020
  • 1. DRUGS OF DISEASES WITH CHRONIC PULMONARY OBSTRUCTION, H 1/-ANTIHISTAMINES.
  • Lecture content: Effects of histamine and how to antagonize it. Classification of H1-antihistamines. Pharmacological review of drugs used in the therapy of diseases with chronic pulmonary obstruction.
  • 25. 2. 2020
  • 2. INTRODUCTION TO PSYCHOPHARMACOLOGY, ANTIPSYCHOTICS, ANTIPARKINSONICS
  • Lecture content: History and classification of psychotropic substances. Antipsychotics, antiparkinsonics – basic pharmacological review.
  • 3. 3. 2020
  • 3. ANTIDEPRESSANTS
  • Lecture content: Pharmacological review of antidepressants and their clinical use.
  • 10. 3. 2020
  • 4. ANXIOLYTICS, HYPNOSEDATIVES, ANTICONVULSANTS .
  • Lecture content: Anxiolytics, hypnosedatives, anticonvulsants - basic pharmacological review. The possibilities of modulation of GABAergic neurotransmission.
  • 17. 3. 2020
  • 5. ANTI-INFECTIVES I - ANTIBIOTICS
  • Lecture content: Introduction/principles of ATB therapy, modes of resistance, pharmacological review of single groups of ATBs.
  • 24. 3. 2020
  • ANTI-INFECTIVES II – ANTIMYCOTICS AND ANTIVIRALS
  • Lecture content: Systemic and local antimycotics; antiherpetics; pharmacotherapy of influenza; antiretrovirals; therapy of RSV and viral hepatitis – pharmacological review.
  • 31. 3. 2020 7. PHARMACOLOGY OF GIT – ULCER DISEASE, ANTIEMETICS, ANTIDIARRHEALS AND LAXATIVES
  • Lecture content: Pharmacological review of drugs acting on GIT.
  • 7. 4. 2020
  • 8. CYTOSTATICS AND TARGETED THERAPY IN ONCOLOGY
  • Lecture content: Introduction. Classification of cytostatics according to their mechanisms of action. Mechanisms of resistance to anticancer drugs. Role of single nucleotide polymorphisms (SNPs) and TDM in oncology. Basic pharmacological properties of selected cytostatics. Principles of targeted therapy in oncology. Monoclonal antibodies. Protein kinase inhibitors. Targeted immunotherapy.
  • 14. 4. 2020
  • 9. ANTIANGIAL DRUGS
  • Lecture content: Pharmacological review of drugs used in the treatment of both acute and chronic ischemic heart disease.
  • 21. 4. 2020
  • 10. ANTIHYPERTENSIVES
  • Lecture content: Pharmacological review of antihypertensives with special focus on drugs interfering with RAAS and diuretics. Second-line antihypertensives.
  • 28. 4. 2020
  • 11. DRUGS OF HEART FAILURE, ANTIARRHYTHMICS
  • Lecture content: Review of drugs used in the therapy of acute and chronic heart failure, Pharmacological review of antiarrhythmics.
  • 5. 5. 2020
  • 12. DRUGS INFLUENCING HEMOSTASIS
  • Lecture content: Pharmacological review of anticoagulants, antiplatelets, fibrinolytics, and hemostatics
  • 12. 5. 2020
  • 13. THERAPY OF INTOXICATIONS, SUBSTANCE ADDICTION
  • Lecture content: Review of most common intoxications and their symptomatology. General principles of poisoning management. Specific antidotes in poisoning therapy. Types of addiction, therapy of substance abuse.
  • 19. 5. 2020
  • 14. DRUG-DRUG INTERACTIONS
  • Lecture content: Classification of drug-drug interaction, evaluation of clinical relevance and seriousness oc drug interactions, management of drug interactions, possibilities of drug interactions monitoring, case-reports.
  • 26. 5. 2020
  • 15. PHYTOPHARMACOLOGY AND PHARMACOGNOSY
  • Lecture content: Natural sources of medicines, selected groups of herbal active components, herbal preparations. The most common herbal poisons.
Literature
    required literature
  • RANG, H. P. Rang & Dale's pharmacology. 8th ed. [Edinburgh]: Churchill Livingstone, 2016. xv, 760. ISBN 9780702053627. info
    recommended literature
  • WHALEN, Karen. Pharmacology. Edited by Richard Finkel - Thomas A. Panavelil. 6th ed. Philadelphia, Pa.: Lippincott Williams & Wilkins, 2015. xi, 664. ISBN 9781451191776. info
    not specified
  • Exam question outlines in the IS
  • Study materials in the IS, course aVLFA0822p and aVLFA0822c
Teaching methods
lectures
Assessment methods
The final evaluation of the course contains also results of the tests from practicals of both semesters and results of colloquium test.

The final mark is calculated by following method:

Relative weight of the mark from tests: 30 %
Relative weight of the mark from oral exam: 70 %

To calculate mark from the tests the following method will be used:
The summary score from all tests in courses VLFA07212c, VLFA07212p, VLFA08222c, and VLFA08222p is 230 pts. Minimum to pass through the course to the oral exam is 116 pts.
A = 205-230 pts
B = 185-204 pts
C = 155-184 pts
D = 140-154 pts
E = 117-139 pts
F = less than 116 pts

To calculate mark from the oral examthe following method will be used:
Three different questions are chosen by students from three different sets of questions at oral exam. Moreover the student answers additional questions of examinator. Drawn questions from General and Special pharmacology and the additional questions have relative weight of 30 %. The question on essential drugs has realtive weight 10 % in the final mark of the oral exam. When student is evaluated by F for any of these questions the overall rating of oral exam is also F.

In case of success with the ROPOT test, but classification F from the oral part, students enter the oral part next time and for the final mark the score from the last ROPOT attempt is used.
Language of instruction
English
Further comments (probably available only in Czech)
The course is taught annually.
Information on the extent and intensity of the course: 30.
Listed among pre-requisites of other courses
Teacher's information

General pharmacology:

1. Pharmacology, sub-branches, origin of drugs, drug names.

2. Types of pharmacotherapy, rules of rational and safe pharmacotherapy. The question of drug misuse.

3. Preclinical and clinical trials, stages.

4. Basic legislation related to drug use, Sources of information on drugs and medicinal products.

5. Solid and gaseous pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics.

6. Semi-solid and liquid pharmaceutical drug dosage forms - overview and their influence on pharmacokinetics and pharmacodynamics.

7. Routes of drug administration – overview, characteristics.

8. Drug absorption, presystemic elimination, drug bioavailability.

9. Drug distribution, volume of distribution, redistribution. General principles of drug movement through the body.

10. Drug elimination, processes of the first and zero order, drug accumulation.

11. Drug biotransformation – stages, examples.

12. Drug excretion (ways of excretion, possibilities of their influence).

13. Therapeutic monitoring of drugs (TDM).

14. Pharmacokinetics of single, repeated and continual drug administration.

15. Modes of drug action

16. Inhibition and induction of enzymes in pharmacokinetics and pharmacodynamics of drugs – examples.

17. Synergism and antagonism in drug effect (pharmacokinetics, pharmacodynamics).

18. Dose – response curves, types of doses, drug anamnesis, patient‘s adherence.

19. Adverse drug reactions (types, categories, examples).

20. Pharmacovigilance, drug safety.

21. Primary resistance of the patient to the treatment. Influence of repeated administration on drug efficacy - examples of tolerance and tachyphylaxis.

22. Factors influencing the drug effect – examples.

23. Pharmacotherapy in elderly, the influence of co-morbidities on drug effect, polypharmacy.

24. Pharmacotherapy in pediatric population, in breastfeeding women. Drugs influencing breast feeding.

25. Pharmacotherapy in pregnancy, drug teratogenicity.

26. Pharmacogenetics, influence of genetic polymorphisms on pharmacokinetics and pharmacodynamics of drugs.

27. Drug interactions - overview, examples.

28. Principles of biological treatment – classification, technology, examples of clinical use.

Special pharmacology:

1. Sympathomimetics - overview of single classes and their indications, examples of drugs

2. Sympatholytics - overview of single classes and their indications, examples of drugs

3. Cholinomimetics

4. Cholinolytics

5. Antispasmodics - GIT + UGT

6. Opioid analgesics

7. NSAIDs, non-opioid analgesics, antimigraine agents

8. Antiuratics, antirheumatics incl. DMARDs

9. General anesthetics

10. Local anesthetics

11. Muscle relaxants

12. Antidiabetics (except insulins)

13. Insulins

14. Sex hormones and hormones of H-P axis

15. Uterotonics and tocolytics

16. Glucocorticoids

17. Immunostimulants + immunosuppressants (except glucocorticoids)

18. Drugs used in osteoporosis, pharmacology of thyroid gland

19. Antiasthmatics, drugs used in COPD

20. Antitussives, mucoactive drugs

21. H1 antihistamines

22. Antipsychotics

23. Drugs of neurogenerative diseases (Parkinson’s disease; dementia)

24. Antidepressants - iMAO+SSRI+NDRI

25. Antidepressants - tricyclic, NASSA, MASSA, SARI, SNRI, NARI, SMS

26. Nootropics, cognitive enhancers

27. Psychotomimetics, drugs used in ADHD

28. Anticonvulsants

29. Hypnosedatives, anxiolytics

30. Principles of antibacterial therapy – overview, modes of action, resistance, MIC, MBC

31. Penicillins, carbapenems

32. Cephalosporines, monobactams

33. Lincosamides, glycopeptides, polymyxins

34. Tetracyclines + related ATBs, amphenicoles

35. Macrolides and related ATBs

36. Aminoglycosides

37. Sulphonamides, nitrofurans and nitroimidazoles

38. Quinolones, antituberculotics

39. Antimycotics

40. Dermatologics – overview of classes, drugs and effects

41. Antivirotics

42. Antiemetic drugs, prokinetics, antivertigo drugs

43. Laxatives, antidiarrhoics, drugs of infectious diarrhoeas

44. Antiulcer agents, hepatoprotectives and drugs influencing the production and excretion of bile

45. Drugs for inflammatory bowel disease

46. Alkylating cytostatics and other drugs aiming on DNA in oncology

47. Antimetabolites + hormonal therapy in oncology

48. Targeted treatment in oncology

49. Biological treatment of autoimmune diseases

50. Hypolipidemics, anti-obesity drugs

51. Antiangial agents

52. Antihypertensives – drugs targeting RAAS

53. Antihypertensives – diuretics and aldosterone antagonists

54. Antihypertensives beta blockers + central antihypertensives

55. Antihypertensives - calcium channel blockers, α1 lytics

56. Antiarrhythmics

57. Drugs used in heart failure

58. Antiplatelet agents

59. Fibrinolytics, antifibrinolytics

60. Anticoagulants

61. Antianemics, hemostatics

62. Drugs causing addiction

63. Drugs used in the treatment of addiction

64. General principles of drug poisoning, specific antidotes and their mechanisms of action

65. Drugs used in erectile dysfunction and BHP

66. Vitamins

67. Antiglaucomatics and cycloplegics

„Essential drugs“

1. adrenalin/noradrenalin

2. dobutamine

3. ephedrine/pseudoephedrine

4. phenylephrine

5. oxymetazoline

6. methyldopa

7. salbutamol

8. doxazosin

9. metoprolol

10. timolol

11. atropine

12. butylscopolamine

13. fenpiverine/pitofenone

14. pilocarpine

15. rivastigmine

16. physostigmine

17. solifenacin

18. paracetamol/ASA

19. ibuprofen/diclofenac

20. indomethacin

21. nimesulide/meloxicam

22. buprenorphine

23. morphine/naloxone

24. sufentanil

25. tramadol

26. metamizole

27. allopurinol

28. sumatriptan

29. desflurane

30. propofol

31. ketamine

32. procaine/lidocaine

33. suxamethonium

34. prilocaine

35. metformin

36. glimepiride

37. sitagliptin

38. insulin lispro

39. insulin glargine

40. ethinylestradiol

41. cyproterone

42. tibolone

43. tamoxifen

44. hexoprenaline

45. oxytocin

46. levonorgestrel

47. dexamethasone

48. prednisone

49. cyclosporine

50. interferons

51. methotrexate

52. ibandronic acid

53. acetylcysteine

54. codeine

55. butamirate

56. ipratropium-bromide

57. bisulepine/cetirizine

58. haloperidol

59. olanzapine

60. aripiprazole

61. levodopa/carbidopa

62. metoclopramide

63. escitalopram

64. amitriptyline

65. mirtazapine

66. lithium

67. methylphenidate

68. piracetam/pyritinol

69. diazepam

70. buspirone

71. gabapentin/pregabalin

72. carbamazepine

73. valproic acid

74. zolpidem

75. midazolam

76. phenoxymethylpenicillin

77. co-amoxicillin

78. piperacillin

79. cefuroxime

80. meropenem

81. vancomycin

82. doxycycline

83. clarithromycin

84. azithromycin

85. gentamicin

86. cotrimoxazole

87. ciprofloxacin

88. rifampicin

89. terbinafine

90. caspofungin

91. amphotericin B

92. fluconazole

93. acyclovir

94. zidovudine

95. isotretinoin

96. salicylic acid

97. ondansetron

98. moxastine

99. pantoprazole

100. famotidine

101. lactulose

102. aprepitant

103. loperamide

104. betahistine

105. cinnarizine

106. cyclophosphamide

107. methotrexate

108. 5-fluorouracil

109. paclitaxel

110. doxorubicin

111. cisplatin

112. trastuzumab

113. imatinib

114. interferon alfa

115. nivolumab

116. atorvastatin

117. fenofibrate

118. ezetimibe

119. isosorbid dinitrate/nitroglycerin

120. hydrochlorothiazide/indapamide

121. furosemide

122. spironolactone

123. amlodipine

124. perindopril

125. telmisartan

126. digoxin

127. amiodarone

128. verapamil

129. levosimendan

130. warfarin

131. enoxaparin

132. clopidogrel

133. dabigatran

134. rivaroxaban

135. alteplase

136. methadone

137. buprenorphine

138. nalmefene

139. naltrexone

140. finasteride

141. sildenafil

The course is also listed under the following terms Spring 2018, spring 2019, spring 2020.
  • Enrolment Statistics (spring 2021, recent)
  • Permalink: https://is.muni.cz/course/med/spring2021/aVLFA0822p